West Family Investments Inc. Has $810,000 Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

West Family Investments Inc. trimmed its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 4.5% in the fourth quarter, Holdings Channel reports. The fund owned 1,137 shares of the biopharmaceutical company’s stock after selling 53 shares during the period. West Family Investments Inc.’s holdings in Regeneron Pharmaceuticals were worth $810,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Rakuten Securities Inc. boosted its position in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the last quarter. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $26,000. Truvestments Capital LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $39,000. Valley Wealth Managers Inc. bought a new position in Regeneron Pharmaceuticals during the 3rd quarter worth $49,000. Finally, Larson Financial Group LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 127.3% in the 3rd quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 28 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Piper Sandler cut their price objective on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. TD Cowen cut their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday, February 4th. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, Wells Fargo & Company cut their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $698.44 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $642.00 and a one year high of $1,211.20. The firm has a market capitalization of $76.36 billion, a price-to-earnings ratio of 18.25, a PEG ratio of 2.34 and a beta of 0.08. The business has a 50-day simple moving average of $696.22 and a 200 day simple moving average of $856.82. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the company posted $11.86 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.